Jump to Main Contents

Home > Organization > Fundamental Innovative Oncology Core > Biomarker and Therapeutic Target Research Core > Department of Biomarkers for Early Detection of Cancer > Research Papers

Research Papers


  1. Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, et al. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget. 2017. PMID: 28611302 DOI: 10.18632/oncotarget.18297
  2. Shiraishi H, Fujiwara Y, Kakuya T, Tsuta K, Motoi N, Miura N, et al. Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomark Med. 2017. PMID: 28658966 DOI: 10.2217/bmm-2017-0150
  3. Kakuya T, Mori T, Yoshimoto S, Watabe Y, Miura N, Shoji H, et al. Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer. Int J Oral Maxillofac Surg. 2017;46(8):968-76. PMID: 8385383 DOI: 10.1016/j.ijom.2017.03.001
  4. Hirata Y, Kobayashi T, Nishiumi S, Yamanaka K, Nakagawa T, Fujigaki S, et al. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Clin Chim Acta. 2017;468:98-104. PMID: 28215548 DOI: 10.1016/j.cca.2017.02.011


  1. Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, et al. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. Plos One. 2016;11(8). PMID: 27579675 DOI: 10.1371/journal.pone.0161009
  2. Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, et al. A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. Cancer Chemoth Pharm. 2016;78(3):567-75. PMID: 27438067 DOI: 10.1007/s00280-016-3111-x
  3. Miura N, Kamita M, Kakuya T, Fujiwara Y, Tsuta K, Shiraishi H, et al. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget. 2016;7(22):33165-78. PMID: 27121206 DOI: 10.18632/oncotarget.8890
  4. Honda K, Srivastava S. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomark Med. 2016;10(11):1197-207. PMID: 27673558 DOI: 10.2217/bmm-2016-0209


  1. Watanabe T, Ueno H, Watabe Y, Hiraoka N, Morizane C, Itami J, et al. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Brit J Cancer. 2015;112(4):704-13. PMID: 25602965 DOI: 10.1038/bjc.2014.623
  2. Okamoto N, Suzuki H, Kawahara K, Honda K, Miura N, Hirashima T, et al. The Alternatively Spliced Actinin-4 Variant as a Prognostic Marker for Metastasis in Small-cell Lung Cancer. Anticancer research. 2015;35(3):1663-7. PMID: 25750325
  3. Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, et al. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci Rep. 2015;5:15921. PMID: 26549697 DOI: 10.1038/srep15921


  1. Honda K. The biological role of actinin-4 (ACTN4) in malignant phenotypes of cancer. Cell Biosci. 2015;5:41. PMID: 26288717 DOI: 10.1186/s13578-015-0031-0
  2. Watabe Y, Mori T, Yoshimoto S, Nomura T, Shibahara T, Yamada T, et al. Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. Cancer Med-Us. 2014;3(3):613-22. PMID: 24574362 DOI: 10.1002/cam4.214
  3. Tanaka N, Yamashita T, Yamamoto S, Matsunobu T, Tsuda H, Honda K, et al. Histological growth pattern of and alpha-actinin-4 expression in thyroid cancer. Anticancer research. 2014;34(6):3157-63. PMID: 24922688
  4. Masuda M, Chen WY, Miyanaga A, Nakamura Y, Kawasaki K, Sakuma T, et al. Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol Cell Proteomics. 2014;13(6):1429-38. PMID: 24643969 DOI: 10.1074/mcp.M113.033845
  5. Kobayashi E, Satow R, Ono M, Masuda M, Honda K, Sakuma T, et al. MicroRNA expression and functional profiles of osteosarcoma. Oncology. 2014;86(2):94-103. PMID: 24457375
  6. Fukushima S, Yoshida A, Honda K, Maeshima AM, Narita Y, Yamada T, et al. Immunohistochemical actinin-4 expression in infiltrating gliomas: association with WHO grade and differentiation. Brain Tumor Pathol. 2014;31(1):11-6. PMID: 23504125 DOI: 10.1007/s10014-013-0139-z


  1. Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol. 2013;26(8):1041-50. PMID: 23558573 DOI: 10.1038/modpathol.2013.54
  2. Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, et al. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(10):2594-600. PMID: 23899839 DOI: 10.1093/annonc/mdt293
  3. Miyanaga A, Honda K, Tsuta K, Masuda M, Yamaguchi U, Fujii G, et al. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(1):84-90. PMID: 22887464 DOI: 10.1093/annonc/mds215
  4. Makuuchi Y, Honda K, Osaka Y, Kato K, Kojima T, Daiko H, et al. Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci. 2013;104(8):1045-51. PMID: 23648090 DOI: 10.1111/cas.12187
  5. Honda K, Ono M, Shitashige M, Masuda M, Kamita M, Miura N, et al. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol. 2013;43(2):103-9. PMID: 23248327 DOI: 10.1093/jjco/hys200


  1. Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, et al. ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. Histopathology. 2012;60(7):1073-83. PMID: 22348389 DOI: 10.1111/j.1365-2559.2011.04163.x
  2. Takakura M, Yokomizo A, Tanaka Y, Kobayashi M, Jung G, Banno M, et al. Carbonic anhydrase I as a new plasma biomarker for prostate cancer. ISRN Oncol. 2012;2012:768190. PMID: 23213568 DOI: 10.5402/2012/768190
  3. Satow R, Shitashige M, Jigami T, Fukami K, Honda K, Kitabayashi I, et al. beta-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells. Gastroenterology. 2012;142(3):572-81. PMID: 22155184 DOI: 10.1053/j.gastro.2011.11.041
  4. Sakane A, Abdallah AA, Nakano K, Honda K, Ikeda W, Nishikawa Y, et al. Rab13 small G protein and junctional Rab13-binding protein (JRAB) orchestrate actin cytoskeletal organization during epithelial junctional development. J Biol Chem. 2012;287(51):42455-68. PMID: 23100251 DOI: 0.1074/jbc.M112.383653
  5. Honda K, Okusaka T, Felix K, Nakamori S, Sata N, Nagai H, et al. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. PLoS One. 2012;7(10):e46908. PMID: 23056525 DOI: 10.1371/journal.pone.0046908